Abstract
Electronic nose (eNose) and nuclear magnetic resonance (NMR)-based metabolomics seem to be able to identify metabolic and inflammatory profiles in patients with chronic obstructive diseases. The hypothesis arises from three recent studies using two different methods in patients with asthma and chronic obstructive pulmonary diseases (COPD), opening promising diagnostic perspectives. The possibility that the use of eNose and NMR-based metabolomics might provide clinical/inflammatory characteristics is intriguing. This might classify specific phenotypes of chronic airway disease regardless of the diagnosis asthma or COPD, therefore suggesting therapeutical targets for a personalized respiratory medicine through more efficient "tailored" strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
